Clinical Trial Update: R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

This update describes a Phase 1 trial of R-5780-01 in combination with PD-1 checkpoint inhibitors for solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoma
• Basal Cell Carcinoma
• Melanoma
• Solid Tumor
• Squamous Cell Carcinoma

Drugs mentioned

• R-5780-01

Snippet

Sponsor: Rise Therapeutics LLC | Conditions: Solid Tumor, Adult, Solid Tumor | Phase 1 | Status: RECRUITING